ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Aligos Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$4.84−0.02 (-0.41%)
Close on Oct 19, 2026
- Market cap
- $50.49M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
18.4%
2M of 12M shares
Institutional holders
31
5 new, 8 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Deep Track Capital, LP | 7,295,967 | 9.99% | 13G (passive) | Oct 23, 2023 |
| Alyeska Investment Group, L.P. | 530,000 | 9.99% | 13G (passive) | Mar 31, 2025 |
| Sio Capital Management, LLC | 335,937 | 5.46% | 13G (passive) amendment | Dec 31, 2025 |
| Adage Capital Management, L.P. | 325,000 | 9.38% | 13G (passive) amendment | Dec 31, 2024 |
| Lawrence M. Blatt | 316,228 | 5.60% | 13D (active) | Jun 16, 2026 |
| Roche Holding Ltd | 11,025,941 | 15.35% | 13G (passive) amendment | Oct 25, 2023 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ALGS | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 444,110 | 3.56% | $2.56M | – | 0.04% |
| Alyeska Investment Group, L.P. | 412,000 | 3.30% | $2.38M | – | 0.01% |
| Sio Capital Management, LLC | 327,237 | 2.62% | $1.89M | – | 0.31% |
| Marshall Wace, Llp | 246,579 | 1.97% | $1.42M | −20,556 | 0.00% |
| Woodline Partners LP | 177,362 | 1.42% | $1.02M | – | 0.00% |
| Vanguard Capital Management LLC | 175,543 | 1.41% | $1.01M | −2,719 | 0.00% |
| Baker Bros. Advisors LP | 83,055 | 0.67% | $479.23K | – | 0.00% |
| Hhlr Advisors, Ltd. | 76,247 | 0.61% | $439.95K | – | 0.05% |
| D. E. Shaw & Co., Inc. | 66,463 | 0.53% | $383.49K | +55,485 | 0.00% |
| UBS Group AG | 59,986 | 0.48% | $346.12K | +22,925 | 0.00% |
| Geode Capital Management, LLC | 47,173 | 0.38% | $272.32K | −2,802 | 0.00% |
| Jane Street Group, LLC | 32,402 | 0.26% | $186.96K | New | 0.00% |
| BlackRock, Inc. | 30,292 | 0.24% | $174.79K | +17,252 | 0.00% |
| Vanguard Fiduciary Trust Co | 28,612 | 0.23% | $165.09K | +175 | 0.00% |
| Dimensional Fund Advisors LP | 21,044 | 0.17% | $121.42K | New | 0.00% |
| Verition Fund Management LLC | 18,887 | 0.15% | $108.98K | – | 0.00% |
| Trexquant Investment LP | 12,339 | 0.10% | $71.20K | New | 0.00% |
| Renaissance Technologies LLC | 10,800 | 0.09% | $62.32K | −89,650 | 0.00% |
| Rockefeller Capital Management L.P. | 10,000 | 0.08% | $57.70K | – | 0.00% |
| Federation des caisses Desjardins du Quebec | 4,650 | 0.04% | $26.83K | +3,700 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 31 | 2M | 18.4% | 5 / 7 | 7 / 8 | 0M | 1M |
| Q1 2026 | 34 | 3M | 22.2% | 6 / 8 | 9 / 9 | 1M | 0M |
| Q4 2025 | 39 | 3M | 22.5% | 11 / 9 | 7 / 5 | 1M | 1M |
| Q3 2025 | 33 | 3M | 21.2% | 5 / 11 | 7 / 9 | 0M | 0M |
| Q2 2025 | 37 | 3M | 21.7% | 9 / 10 | 8 / 7 | 1M | 1M |
| Q1 2025 | 35 | 3M | 26.4% | 11 / 9 | 9 / 8 | 2M | 1M |
| Q4 2024 | 33 | 2M | 13.0% | 12 / 10 | 4 / 6 | 0M | 1M |
| Q3 2024 | 27 | 2M | 13.5% | 27 / 0 | 0 / 0 | 2M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ALGS | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 128,770 | 1.03% | $743.00K | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 46,773 | 0.37% | $269.88K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 24,809 | 0.20% | $141.41K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 16,428 | 0.13% | $94.79K | 0.01% | Jun 30, 2026 |
| U.S. Micro Cap Portfolio | 8,329 | 0.07% | $35.23K | 0.00% | Jul 31, 2026 |
| Fidelity Total Market Index Fund | 7,553 | 0.06% | $43.05K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 6,141 | 0.05% | $35.00K | 0.00% | May 31, 2026 |
| U.S. Small Cap Portfolio | 3,573 | 0.03% | $15.11K | 0.00% | Jul 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 3,569 | 0.03% | $20.34K | 0.00% | May 31, 2026 |
| Strategic Advisers U.S. Total Stock Fund | 3,200 | 0.03% | $18.24K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 2,810 | 0.02% | $11.89K | 0.00% | Jul 31, 2026 |
| U.S. Vector Equity Portfolio | 2,093 | 0.02% | $8.85K | 0.00% | Jul 31, 2026 |
| Dimensional U.S. Core Equity 2 ETF | 1,855 | 0.01% | $7.85K | 0.00% | Jul 31, 2026 |
| Avantis U.S. Small Cap Equity ETF | 1,427 | 0.01% | $8.13K | 0.00% | May 31, 2026 |
| Dimensional US Sustainability Core 1 ETF | 1,149 | 0.01% | $4.86K | 0.00% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Lawrence Blatt | President and CEO, Director | 1,866,092 | 14.94% | Mar 11, 2026 |
| Nikhil Aneja | Principal Accounting Officer | – | – | Mar 11, 2026 |
| Julian A. Symons | See Remarks | 394,064 | 3.16% | Mar 11, 2026 |
| Lesley Ann Calhoun | See Remarks | – | – | Mar 11, 2026 |
| Margarita Chavez | Director | – | – | Jun 29, 2026 |
| James Paul Scopa | Director | 183,083 | 1.47% | Jun 29, 2026 |
| Carole Nuechterlein | Director | 11,025,941 | 88.28% | Jun 29, 2026 |
| Heather Preston | Director | – | – | Jun 29, 2026 |
| Bridget A. Martell | Director | – | – | Jun 29, 2026 |
| Peter Hirth | Director | 59,549 | 0.48% | Jun 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Lawrence Blatt Chief Executive Officer, Director | Oct 25, 2023 | Award | +610,277 | $0.76 | $463.81K | 1,847,575 |
| Carole Nuechterlein Director, 10% owner | Oct 25, 2023 | Buy | +7,933,601 | $0.76 | $6.03M | 11,025,941 |
| James Paul Scopa Director | Oct 25, 2023 | Award | +183,083 | $0.76 | $139.14K | 183,083 |
| Thomas Woiwode Director | Jun 11, 2021 | Other | +8,383 | – | – | 8,383 |
| Thomas Woiwode Director | Jun 11, 2021 | Other | −9,719 | – | – | 0 |
| Thomas Woiwode Director | Jun 11, 2021 | Other | +9,719 | – | – | 9,719 |
| Thomas Woiwode Director | Jun 11, 2021 | Other | +2,226 | – | – | 4,452 |
| Thomas Woiwode Director | Jun 11, 2021 | Other | −8,383 | – | – | 0 |
| Thomas Woiwode Director | Jun 11, 2021 | Other | −485,979 | – | – | 1,457,937 |
| Thomas Woiwode Director | Apr 26, 2021 | Other | −485,979 | – | – | 1,943,916 |
| Thomas Woiwode Director | Apr 26, 2021 | Other | +9,720 | – | – | 9,720 |
| Thomas Woiwode Director | Apr 26, 2021 | Other | −9,720 | – | – | 0 |
| Thomas Woiwode Director | Apr 26, 2021 | Other | +8,385 | – | – | 8,385 |
| Thomas Woiwode Director | Apr 26, 2021 | Other | −8,385 | – | – | 0 |
| Thomas Woiwode Director | Apr 26, 2021 | Other | +2,226 | – | – | 2,226 |
| Holdings A/S Novo 10% owner | Oct 20, 2020 | Buy | +200,000 | $15.00 | $3.00M | 2,614,563 |
| Holdings A/S Novo 10% owner | Oct 20, 2020 | Conversion | +2,414,563 | – | – | 2,414,563 |
| Biomedical Innovation Master Investors (Cayman) I. L.P. Wellington 10% owner | Oct 20, 2020 | Conversion | +1,335,048 | – | – | 1,335,048 |
| Biomedical Innovation Master Investors (Cayman) I. L.P. Wellington 10% owner | Oct 20, 2020 | Conversion | +571,143 | – | – | 1,906,191 |
| Thomas Woiwode Director | Oct 20, 2020 | Conversion | +198,485 | – | – | 662,444 |
| Thomas Woiwode Director | Oct 20, 2020 | Buy | +200,000 | $15.00 | $3.00M | 862,444 |
| Thomas Woiwode Director | Oct 20, 2020 | Conversion | +85,065 | – | – | 2,429,895 |
| Thomas Woiwode Director | Oct 20, 2020 | Conversion | +2,145,991 | – | – | 2,145,991 |
| Thomas Woiwode Director | Oct 20, 2020 | Conversion | +198,839 | – | – | 2,344,830 |
| Thomas Woiwode Director | Oct 20, 2020 | Conversion | +463,959 | – | – | 463,959 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Oct 20, 2020 | Conversion | +260,380 | – | – | 260,380 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Oct 20, 2020 | Conversion | +1,885,611 | – | – | 1,885,611 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Oct 20, 2020 | Buy | +483,267 | $15.00 | $7.25M | 3,116,658 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Oct 20, 2020 | Conversion | +30,939 | – | – | 363,639 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Oct 20, 2020 | Conversion | +72,320 | – | – | 332,700 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Oct 20, 2020 | Buy | +66,733 | $15.00 | $1.00M | 430,372 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Oct 20, 2020 | Conversion | +224,054 | – | – | 2,633,391 |
| Vivo Capital Surplus Fund VIII, L.P. 10% owner | Oct 20, 2020 | Conversion | +523,726 | – | – | 2,409,337 |
| Leonid Beigelman President, Director | Oct 20, 2020 | Conversion | +1,437 | – | – | 18,355 |
| Leonid Beigelman President, Director | Oct 20, 2020 | Conversion | +21,724 | – | – | 236,347 |
| Leonid Beigelman President, Director | Oct 20, 2020 | Conversion | +1,437 | – | – | 18,355 |
| Leonid Beigelman President, Director | Oct 20, 2020 | Conversion | +3,359 | – | – | 16,918 |
| Leonid Beigelman President, Director | Oct 20, 2020 | Conversion | +3,359 | – | – | 16,918 |
| Leonid Beigelman President, Director | Oct 20, 2020 | Conversion | +50,781 | – | – | 214,623 |
| Leonid Beigelman President, Director | Oct 20, 2020 | Conversion | +13,559 | – | – | 13,559 |
| Leonid Beigelman President, Director | Oct 20, 2020 | Conversion | +13,559 | – | – | 13,559 |
| Leonid Beigelman President, Director | Oct 20, 2020 | Conversion | +163,842 | – | – | 163,842 |
| Versant Venture Capital VI, L.P. 10% owner | Oct 20, 2020 | Conversion | +198,839 | – | – | 2,344,830 |
| Versant Venture Capital VI, L.P. 10% owner | Oct 20, 2020 | Conversion | +463,959 | – | – | 463,959 |
| Versant Venture Capital VI, L.P. 10% owner | Oct 20, 2020 | Conversion | +85,065 | – | – | 2,429,895 |
| Versant Venture Capital VI, L.P. 10% owner | Oct 20, 2020 | Conversion | +198,485 | – | – | 662,444 |
| Versant Venture Capital VI, L.P. 10% owner | Oct 20, 2020 | Conversion | +2,145,991 | – | – | 2,145,991 |
| Versant Venture Capital VI, L.P. 10% owner | Oct 20, 2020 | Buy | +200,000 | $15.00 | $3.00M | 862,444 |
| Carole Nuechterlein Director | Oct 20, 2020 | Conversion | +662,799 | – | – | 2,808,790 |
| Carole Nuechterlein Director | Oct 20, 2020 | Conversion | +283,550 | – | – | 3,092,340 |
| Carole Nuechterlein Director | Oct 20, 2020 | Conversion | +2,145,991 | – | – | 2,145,991 |
| Lawrence Blatt Chief Executive Officer | Oct 20, 2020 | Conversion | +41,016 | – | – | 41,016 |
| Lawrence Blatt Chief Executive Officer | Oct 20, 2020 | Conversion | +50,712 | – | – | 91,728 |
| Lawrence Blatt Chief Executive Officer | Oct 20, 2020 | Conversion | +13,671 | – | – | 13,671 |
| Lawrence Blatt Chief Executive Officer | Oct 20, 2020 | Conversion | +13,671 | – | – | 13,671 |
| Lawrence Blatt Chief Executive Officer | Oct 20, 2020 | Conversion | +122,601 | – | – | 122,601 |
| Lawrence Blatt Chief Executive Officer | Oct 20, 2020 | Conversion | +3,394 | – | – | 17,065 |
| Lawrence Blatt Chief Executive Officer | Oct 20, 2020 | Conversion | +1,452 | – | – | 18,517 |
| Lawrence Blatt Chief Executive Officer | Oct 20, 2020 | Conversion | +3,394 | – | – | 17,065 |
| Lawrence Blatt Chief Executive Officer | Oct 20, 2020 | Conversion | +21,695 | – | – | 113,423 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.